Biotech - Spark Newswire

4 minute read

Actinium Activates Radiation Inside the Body for Target Conditioning of Cancer Cells

Today, 2:00 AM

Actinium Pharmaceuticals Inc. (NYSE: ATNM), a clinical-stage biopharmaceutical company, is developing antibody radiation-conjugates (ARCs) to combine the targeting ability of antibodies with the cell-killing ability of radiation.

ATNM

1 minute read

Auris Medical Enters RNA Therapeutics with Trasir Therapeutics Acquisition; Plans To Spin-Off/Divest Existing Programs

By Vandana Singh

Today, 2:00 AM

Auris Medical Holding Ltd (NASDAQ:EARS) has acquired privately-held Trasir Therapeutics Inc, focused on extrahepatic oligonucleotide delivery. The purchase price comprises 0.77…

EARS

1 minute read

Acadia Pharmaceuticals Highlights Publication Of NUPLAZID In Efficacy Data In Parkinsonism And Related Disorders Journal

By Bill Haddad

Today, 2:00 AM

Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) today announced publication of open-label extension (OLE) data from patients experiencing hallucinations and delusions associated with Parkinson's disease psychosis (PDP) who

ACAD

1 minute read

Edesa Biotech’s EB01 Shows Encouraging Interim Results In Dermatitis Trial

By Vandana Singh

Today, 2:00 AM

Edesa Biotech Inc’s (NASDAQ:EDSA) EB01 has met a key interim study parameter as part of an adaptive Phase 2b trial evaluating EB01 as…

EDSA

1 minute read

VBL Therapeutics Stock Jumps on Adding PFS as Second Independent Primary Endpoint in Ovarian Cancer Gene Therapy Trial

By Vandana Singh

Today, 2:00 AM

VBL Therapeutics Ltd (NASDAQ:VBLT) has amended the primary endpoint in the OVAL Phase 3 registration-enabling study of VB-111 (ofranergene obadenovec) gene therapy for…

VBLT

1 minute read

Tonix Pharma Fibromyalgia Treatment Associated with Improvement in Pain, Sleep, Fatigue

By Vandana Singh

Today, 2:00 AM

Tonix Pharmaceuticals Holding Corp (NASDAQ:TNXP) has announced the poster presentation of previously reported results from its Phase 3 RELIEF trial evaluating the TNX-102…

TNXP

1 minute read

Updated Analysis Show Seagen’s Tukysa Extended Median OS to Two Years with Benefits Maintained in Breast Cancer

By Vandana Singh

Today, 2:00 AM

Seagen Inc (NASDAQ:SGEN) has announced that improvements in overall survival (OS) and progression-free survival (PFS) were maintained with long-term follow-up from…

SGEN

5 minute read

The Daily Biotech Pulse: Merck Completes Organon Spin-Off, Auris Repositions As RNA Therapeutic Company With Trasir Purchase, Replimune’s Readout

By Shanthi Rexaline

Today, 2:00 AM

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 2)

AMYT

3 minute read

A Breakthrough in Targeted Cancer Therapy: Lixte Biotechnology Clinical Stage Compound LB-100

By M.J. Walker

Today, 2:00 AM

Dr. John Kovach, the CEO and founder of Lixte Biotechnology Holdings, Inc., expressed excitement for his company’s first-in-class protein phosphatase inhibitor, LB-100 as a new addition to cancer treatment at the Benzinga Global Small Cap Business Conference on May 13, 2021.

LIXT

1 minute read

Oric Pharma’s ORIC-101 Shows Tumor Regression, Prolonged Stable Disease in Multiple Heavily Pretreated Tumors

By Vandana Singh

Today, 2:00 AM

Oric Pharmaceuticals Inc (NASDAQ:ORIC) has announced initial data from an ongoing Phase 1b study evaluating ORIC-101 in combination with nab-paclitaxel, in…

ORIC